Jiangxi Province Key Laboratory of Laboratory Medicine, Department of Laboratory Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
Department of Medical Supply, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
Med Sci Monit. 2018 Oct 22;24:7541-7547. doi: 10.12659/MSM.909772.
BACKGROUND MAD2 is the gene controlling mitosis. Many studies have assessed MAD2 in various types of carcinoma. Antinuclear mitotic spindle apparatus antibody (MSA) and anticentromere antibody (ACA) are related mitotic antibodies, playing roles in autoimmune diseases and carcinomas, but the expression of MAD2, MSA, and ACA in SCLC is unclear. MATERIAL AND METHODS We enrolled 70 SCLC patients, 72 non-small cell lung cancer (NSCLC) patients, and 65 pulmonary nodule (PN) patients. MAD2 expression was measured through agarose electrophoresis and qt-PCR. Antinuclear mitotic spindle apparatus antibody (MSA) and anticentromere antibody (ACA) were detected by indirect immunofluorescence (IIF). RESULTS MAD2 was found both in SCLC and NSCLC. Interestingly, there was a significant difference found between SCLC and NSCLC using qt-PCR (P<0.05). The area under the ROC curve of MAD2 expression was 0.799, with medium diagnostic value. MAD2 expression was related to age, lymphatic metastasis, and survival time, but not with sex. The positivity for MSA and ACA by IIF assay were 37.20% and 34.00%, respectively, in the SCLC group, which were higher than in the NSCLC and pulmonary nodule groups (P<0.05). The kappa values of MSA and ACA with MAD2 expression were 0.73 and 0.65, respectively, with moderate consistency. Combining MAD2 with MSA and ACA enhanced the sensitivity and specificity for diagnosing SCLC. CONCLUSIONS MAD2 expression was found to be involved in carcinogenesis and prognosis of SCLC. The combination of MAD2 with MSA and ACA is useful for early diagnosis and shows promise in treatment of SCLC.
MAD2 是控制有丝分裂的基因。许多研究已经评估了 MAD2 在各种类型的癌中的作用。抗核有丝分裂纺锤体装置抗体（MSA）和抗着丝粒抗体（ACA）是相关的有丝分裂抗体，在自身免疫性疾病和癌中发挥作用，但 SCLC 中 MAD2、MSA 和 ACA 的表达尚不清楚。
我们纳入了 70 例 SCLC 患者、72 例非小细胞肺癌（NSCLC）患者和 65 例肺结节（PN）患者。通过琼脂糖电泳和 qt-PCR 测量 MAD2 的表达。通过间接免疫荧光（IIF）检测抗核有丝分裂纺锤体装置抗体（MSA）和抗着丝粒抗体（ACA）。
MAD2 在 SCLC 和 NSCLC 中均有表达。有趣的是，qt-PCR 显示 SCLC 和 NSCLC 之间存在显著差异（P<0.05）。MAD2 表达的 ROC 曲线下面积为 0.799，具有中等诊断价值。MAD2 表达与年龄、淋巴转移和生存时间有关，但与性别无关。IIF 检测的 SCLC 组 MSA 和 ACA 的阳性率分别为 37.20%和 34.00%，高于 NSCLC 组和肺结节组（P<0.05）。MSA 和 ACA 与 MAD2 表达的kappa 值分别为 0.73 和 0.65，具有中度一致性。将 MAD2 与 MSA 和 ACA 结合起来，提高了诊断 SCLC 的敏感性和特异性。
MAD2 表达参与了 SCLC 的发生和预后。将 MAD2 与 MSA 和 ACA 结合起来有助于早期诊断 SCLC，并在治疗 SCLC 方面具有一定的应用前景。
